Four Atlas Antibodies TripleA Polyclonals used in the study about IDH mutation

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.

Diffusely infiltrating gliomas are classified depending on mutations in isocitrate dehydrogenase (IDH) into IDH-wild-type and IDH-mutated gliomas.  

This study published in Neuro Oncology reports that the IDH mutation status is associated with distinct vascular gene expression signatures: IDH-wild-type low-grade gliomas vessels are molecularly distinct from the vasculature of IDH-mutated low-grade gliomas indicative of ongoing angiogenesis and vascular remodeling.



The results implicate that IDH-wild-type low-grade gliomas may respond differently to anti-angiogenic therapy.


Furthermore, since TGFβ / hypoxia signaling contributes to the altered vascular gene expression, they may represent potential targets for normalizing the vasculature in IDH-wild-type low-grade gliomas.


Four of our TripleA Polyclonals are used in the study:

anti-SLCO2A1 antibody (HPA013742)
anti-LAMB1 antibody (HPA004132)
anti-LAMA4 antibody (HPA015693)
anti-PNP antibody (HPA001625)


Read more in publication: https://lnkd.in/dWhQsF9i